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To investigate the association between cannabis smoking and lung cancer risk, data on 2,159 lung cancer cases and 2,985
controls were pooled from 6 case-control studies in the US, Canada, UK, and New Zealand within the International Lung Can-
cer Consortium. Study-specific associations between cannabis smoking and lung cancer were estimated using unconditional
logistic regression adjusting for sociodemographic factors, tobacco smoking status and pack-years; odds-ratio estimates were
pooled using random effects models. Subgroup analyses were done for sex, histology and tobacco smoking status. The
shapes of dose-response associations were examined using restricted cubic spline regression. The overall pooled OR for
habitual versus nonhabitual or never users was 0.96 (95% CI: 0.66–1.38). Compared to nonhabitual or never users, the sum-
mary OR was 0.88 (95%CI: 0.63–1.24) for individuals who smoked 1 or more joint-equivalents of cannabis per day and 0.94
(95%CI: 0.67–1.32) for those consumed at least 10 joint-years. For adenocarcinoma cases the ORs were 1.73 (95%CI: 0.75–
4.00) and 1.74 (95%CI: 0.85–3.55), respectively. However, no association was found for the squamous cell carcinoma based
on small numbers. Weak associations between cannabis smoking and lung cancer were observed in never tobacco smokers.
Spline modeling indicated a weak positive monotonic association between cumulative cannabis use and lung cancer, but pre-
cision was low at high exposure levels. Results from our pooled analyses provide little evidence for an increased risk of lung
cancer among habitual or long-term cannabis smokers, although the possibility of potential adverse effect for heavy consump-
tion cannot be excluded.
Background
Cannabis is the world’s most widely used illicit substance with
between 119 million and 224 million users worldwide. In 2010,
the proportion reporting use of cannabis in the past year was 2.6–
5% for persons aged 15–64, with highest frequency observed in
Oceania (9.1–14.6%) and North America (10.8%).1 In the US, fre-
quency of cannabis use has continued to rise2 especially among
teenagers, a trend that has been attributed to falling perceived
risk.1 The three main forms of cannabis products are the flower or
herb (marijuana), resin (hashish), and oil (hashish oil), and their
relative levels of consumption vary globally by region. Resin domi-
nates the markets in the Near- and Middle-East as well as South-
west Asia; resin and herb markets are comparable in size in
Northern Africa and Europe; whereas cannabis herb dominates
the rest of the world including North America.1
Lung cancer remains the leading cause of cancer death
worldwide, and use of tobacco is recognized as the main risk
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factor.3–5 Cannabis is mainly consumed by smoking, and
cannabis smoke shares carcinogens with tobacco smoke
including polycyclic aromatic hydrocarbons such as ben-
zo[a]pyrene and phenols.5–7 Different smoking techniques
result in 3-fold higher levels of tar and 5-fold higher levels of
carbon monoxide being retained in the lungs during cannabis
smoking as compared to tobacco smoking.8 Therefore, canna-
bis has been hypothesized to be a risk factor for tobacco-
related cancers including that of the lung. Previous studies
have demonstrated precancerous histological9,10 and molecu-
lar abnormalities11 in the respiratory tracts of cannabis smok-
ers. In addition, in vitro12 and in vivo animal studies have
demonstrated the carcinogenic effects of cannabis or its con-
stituents.13,14 However, epidemiological studies investigating
the association between cannabis smoking and lung cancer
have been limited, sample sizes generally small, and results
conflicting.15–22
Established in 2004, the International Lung Cancer Con-
sortium (ILCCO) brings together an international group of
lung cancer researchers with the aim of sharing comparable
data from ongoing and recently completed lung cancer case-
control and cohort studies from different geographical areas
and ethnicities. One of the key goals of the ILCCO is to
explore potential lung cancer risk factors that are difficult to
evaluate in individual studies. To address the limitations of
prior studies and to further explore the link between canna-
bis smoking and lung cancer development, particularly non-
linear dose-response relations and associations among never
tobacco smokers and other subgroups, we conducted a
pooled analysis based on individual-level data from partici-
pating ILCCO studies.
Methods
Data collection
Details of the International Lung Cancer Consortium and the
requirements for inclusion of studies have been previously
published23 and are available on the Consortium portal
(http://ilcco.iarc.fr). Six ILCCO studies have collected infor-
mation on cannabis smoking and contributed primary data
in this pooled analysis investigating the association between
cannabis smoking and lung cancer risk. Two studies had pre-
viously reported effect estimates for cannabis smoking,15,16
whereas the remaining studies represented unpublished data
for the association of interest. All studies considered primary,
incident and histologically confirmed lung cancer cases. Writ-
ten informed consent was obtained from all study subjects,
and individual study protocols were approved by site-specific
institutional ethic review boards. Deidentified data received
from individual studies were checked for missing values,
inadmissible values, aberrant distributions and inconsisten-
cies. Subjects with unknown age, sex, race or habitual versus
nonhabitual cannabis smoking status were excluded. An
additional 6 subjects, whose joints smoked per day exceeded
40 or lifetime duration of cannabis smoking exceeded 70
years, were deemed outliers or potential data errors based on
the overall distribution. The final pooled analysis sample con-
sisted of 2,159 cases and 2,985 controls.
Statistical methods
Data on individual-level cannabis smoking consumption were
based on self-reported responses to questions on study-
specific questionnaires. We defined lifetime habitual use of
cannabis as having a cumulative consumption of at least 1
joint-year (i.e., equivalent to smoking 1 joint/day for 1 year).
Joint-equivalent was defined as the average cannabis plant
matter contained in a typical joint or 0.75 g/joint when the
unit of reporting was weight or the mode of consumption
was other than joint.24 We also harmonized variables pertain-
ing to total duration (years) and intensity of cannabis smok-
ing (average joint-equivalents smoked per day during periods
of cannabis use); and cumulative cannabis smoking in joint-
years, calculated by multiplying the first two variables for
each subject.
Variables for demographic characteristics and well-
established lung cancer risk factors were harmonized across
studies. Self-reported tobacco smoking status at interview was
defined as never smokers (<100 cigarettes over lifetime or
according to study-specific cut-offs), former smokers
(stopped smoking at least 2 years prior to interview), and
current smokers (smoked within the past 2 years). The latter
two categories make up the ever group in never versus ever
definition for tobacco-smoking status. For current and former
tobacco smokers, cumulative tobacco smoking expressed in
pack-years was calculated as the product of smoking intensity
(pack-equivalent per day) and the sum of smoking periods
over the person’s lifetime. When education level (<3%) or
tobacco pack-years were missing (<5%), values were imputed
using the median of the study-, age-, and sex-specific control
What’s new?
Due to the potential adverse effect of cannabis smoking and its popularity, an investigation of its association with lung cancer
risk is essential to help support appropriate regulations as well as health and social policy responses. The analysis presented
here included the largest data set on cannabis and lung cancer risk to date. Its non-linear dose-response was examined using
restricted cubic spline regression, a first in this line of work. Results provide little evidence for an increased risk of lung can-
cer among habitual or long-term cannabis smokers, although the possibility of potential adverse effect for heavy consumption
cannot be excluded.
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population for education, and the median of the study-, age-,
sex-, and smoking status-specific control population for
pack-years.
The overall association between cannabis smoking (habit-
ual vs. nonhabitual or never users, joint-equivalents per day,
duration, total joint-years, and age of cannabis smoking
onset) and the risk of all lung cancer, adenocarcinoma, and
squamous cell carcinoma (as sample size permitted) was
assessed by odds ratios (OR) and 95% confidence intervals
(CI) obtained from unconditional logistic regression in each
study, adjusting for age, sex, race, highest education, status of
tobacco smoking (never vs. ever) and pack-years of tobacco
smoking (continuous). Because of collinearity and small sam-
ple sizes, models for continuous exposure variables for the
Moffitt Cancer Study and Memorial Sloan-Kettering Cancer
Center Study were restricted to the adjustment of the essen-
tial covariates: age, sex and tobacco smoking pack-years.
Tobacco smoking status (never vs. ever) was additionally
adjusted where possible. Study-specific effect estimates were
pooled across studies using random effect models to account
for heterogeneity between study populations. Interstudy het-
erogeneity was evaluated based on the Q-statistic and I2
statistic.25 When the p-value for heterogeneity across studies
was less than 0.05, influence analysis was performed to evalu-
ate the source of heterogeneity from single studies using
Galbraith plots,26 and excluding the study contributing most
to the Q-statistic. Stratified analyses were done to examine
the associations between cannabis smoking and all lung can-
cer for males and females separately. As an alternative
method to control for confounding by tobacco smoking, as
sample sizes allowed, we also conducted analyses restricted to
those who never smoked tobacco (370 cases and 1,358 con-
trols) by pooling individual level data of never smokers from
all available studies; the associations between cannabis and
lung cancer risk was then assessed with unconditional logistic
regression adjusting for age, sex, highest education, race and
study.
The shapes of nonlinear dose-response associations
between the continuous exposure variables (joint equivalent
per day, duration and overall joint-years) and lung cancer
were examined using restricted cubic spline regression with 5
knots, adjusting for age, sex, race, highest education, tobacco
smoking status (never vs. ever) and pack-years, as well as
study.27 Study-specific multivariable unconditional logistic
regression and pooled analysis for never smokers were con-
ducted in SAS, while the pooled effect estimates and
restricted cubic spline analyses were done in R package.
Results
The characteristics of the 6 participating case-control studies
in ILCCO are summarized in Table 1. Except for one family-
based study, the remaining studies include 2 that used
population-based controls and 3 that used hospital or
clinical-based controls that were frequency matched to cases
on at least age and sex. Four studies were conducted in
North America (3 in the US and 1 in Canada), while the
remaining 2 studies were set in the UK and New Zealand. In
all studies, cannabis consumption was assessed using self-
reported levels on standard questionnaires or surveys. In
total, 2,159 lung cancer cases and 2,985 controls were
included in the analysis. The frequency distributions of
demographic, histology and lung cancer risk factors for both
the total population and never tobacco smokers are summar-
ized in Table 2. Although the average age of controls was
slightly younger than cases (median age was 53.06 10.4 for
controls vs. 57.36 10.5 for cases), subjects were comparable
with respect to sex and race distributions, with over 75% of
subjects being White/Caucasian. As expected, controls were
less likely than cases to have ever smoked tobacco. Squamous
cell carcinoma (n5 394), adenocarcinoma (n5 913) and
small cell lung cancer (n5 273) histologic subtypes make up
over 70% of all cases in the study sample (Table 2).
The frequency distribution of cannabis smoking variables
for the overall population and never tobacco smokers as well
as the pooled risk estimates are summarized in Table 3. The
estimated ORs of all lung cancer associated with habitual
cannabis smokers as compared to nonhabitual or never can-
nabis smokers in the participating studies ranged from 0.57
(95% CI: 0.30–1.07) in the Mount Sinai Hospital-Princess
Margaret Hospital (MSH-PMH) study to 2.17 (95% CI: 1.04–
4.52) in the New Zealand study (Fig. 1). The overall sum-
mary OR was 0.96 (95% CI: 0.66–1.38, p for heterogeneity:
0.17) (Table 3), and there was no detectable heterogeneity in
the effect estimates for studies that used population-based
controls vs. hospital or clinic-based controls (p5 0.24).
Compared to nonhabitual or never users, the pooled OR
was 0.88 (95% CI: 0.63–1.24) for individuals who smoked 1
or more joint-equivalents per day and 1.03 (95%CI: 0.54–
1.98) for individuals who smoked cannabis for 20 years or
more (Table 3) for all lung cancer cases. Also, compared to
nonhabitual or never users, the OR for those who started
smoking cannabis before 19 years of age was 0.86 (95% CI:
0.62–1.19).
In general, sex-specific analyses yielded results comparable
to those obtained for all lung cancer cases and were therefore
not presented in detail. For example, compared to nonhabi-
tual or never cannabis users, the ORs for habitual users are
0.84 (95%CI: 0.60, 1.18) for men and 0.94 (95%CI: 0.62,
1.40) for women. The OR for those who smoked cannabis
more than 20 years was 0.80 (95%CI: 0.55, 1.16) for men
and 1.05 (95%CI: 0.48, 2.82) for women.
No overall association between cannabis smoking and all
lung cancer was detected among never tobacco smokers;
habitual versus nonhabitual or never user OR was 1.03 (95%
CI: 0.51–2.08). Effect estimates for the other categorical can-
nabis variables were too imprecise to be informative due to
the small numbers of exposed cases. For example, the OR
was 1.64 (95%CI: 0.45–6.00) for those who smoked 20 years
or more versus those nonhabitual or never smokers (Table
3), and it was 0.54 (95% CI: 0.12–2.55) for 10 or more joint-
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years of cannabis use versus less than 1 joint-year. The
majority of the never tobacco-smoking lung-cancer cases are
female (272 out of a total of 370), and restricting the analysis
to female nontobacco smokers yielded comparable results:
Compared to nonhabitual or never users, the OR was 0.94
(95%CI: 0.62, 1.40) for habitual cannabis users and 1.05
(95%CI: 0.48, 2.28) for those who smoked for 20 years or
more.
The results for the largest histologic subgroup, adenocarci-
noma, are presented in Table 4. There was a suggestive asso-
ciation between high intensity and cumulative cannabis
smoking on adenocarcinoma lung cancer. Compared to non-
habitual or never users, the OR for users who smoked one or
more joint-equivalents per day was 1.73 (95% CI: 0.75–4.00),
and OR for those with cumulative exposure of 10 joint-years
or more was 1.74 (95% CI: 0.85–3.55) (Table 4). Nonetheless,
we observed little association with the duration of cannabis
smoking; the OR was 1.08 (95% CI: 0.60–1.96) for those who
smoked for 20 years or more. Only 4 of the studies have suf-
ficient data for squamous cell carcinoma. Compared to non-
habitual or never users, the estimated OR for squamous cell
carcinoma was 1.55 (95%CI: 0.35–6.87) for those who
smoked one or more joint-equivalents per day and 1.58
(95%CI: 0.48–5.20) for smokers of more than 20 years. The
estimated OR for the association between cumulative expo-
sure of 10 or more joint-years (vs. less than 1 joint-year) and
lung cancer was 2.35 (95%CI: 0.48–11.46). The confidence
intervals were very wide due to smaller sample sizes of squa-
mous cell carcinoma.
Use of restricted cubic splines to examine the dose-
response associations between cannabis use and lung-cancer
incidence did not exhibit monotonic associations for average
Table 2. Frequency distribution of demographic characteristics, histology and smoking variables
All subjects Never tobacco smokers
Cases
(n52,159)
Controls
(n52,985)
Cases
(n5370)
Controls
(n51,358)
No. (%) No. (%) No. (%) No. (%)
Age1 groups, years
<50 366 (17) 956 (32) 88 (24) 492 (36)
50–59 985 (46) 1327 (44) 130 (35) 570 (42)
60–69 431 (20) 522 (17) 74 (20) 216 (16)
70 377 (17) 180 (6) 78 (21) 80 (6)
Sex
Male 1080 (50) 1572 (53) 98 (26) 635 (47)
Female 1079 (50) 1413 (47) 272 (74) 723 (53)
Race
White/Caucasian 1723 (80) 2323 (78) 222 (60) 1040 (77)
Black/African American 150 (7) 255 (9) 23 (6) 115 (8)
Other 286 (13) 407 (14) 125 (34) 203 (15)
Education level
Low (elementary school) 373 (17) 195 (7) 45 (12) 62 (5)
Medium (up to high school completion) 836 (39) 977 (33) 119 (32) 399 (29)
High (postsecondary education or higher) 950 (44) 1813 (61) 206 (56) 897 (66)
Smoking Status
Never smoker 370 (17) 1358 (46) 370 (100) 1358 (100)
Ever smoker
Former smoker 678 (31) 938 (32)
Current smoker 1089 (50) 663 (22)
Histology
Squamous cell carcinoma 394 (18) 21 (6)
Adenocarcinoma 913 (42) 226 (61)
Small cell carcinoma 273 (13) 9 (2)
Other 579 (27) 114 (31)
1Age at diagnosis for cases and age at interview for controls.
Abbreviation: No.: number.
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joints per day or duration of use (Figs. 2a and 2b). There
was, however, a positive monotonic association between
joint-years of cannabis use and lung cancer (Fig. 2c); but the
95% confidence bands were wide, especially for higher expo-
sure levels.
Discussion
In this study, we harmonized and pooled individual-level
data from 6 ILCCO studies and examined the association
with lung cancer for cannabis smoking status, age of start,
intensity, duration and cumulative exposure in all subjects
and subgroups by sex and histologic subtype where sample
size allowed, and also separately for never tobacco smokers.
In our pooled results, we found little or no association
between the intensity, duration, cumulative consumption or
age of start of cannabis smoke and the risk of lung cancer in
all subjects or never smokers, and suggestive association for
adenocarcinoma. The evidence for the association with other
histological subtypes is limited by the small sample size. In
the spline analyses, there was a weak increasing trend over
long-term and high levels of cumulative cannabis smoking
exposure. The confidence intervals were wide due to the lim-
ited number of observations at the high exposure levels, but
the results are more compatible with an association with lung
cancer at high levels of cannabis exposure than with no asso-
ciation. In addition, misclassification of cannabis use no
doubt occurred and may have flattened or distorted the dose-
response relation.
The consumption of psychoactive substances such as can-
nabis and tobacco are often highly correlated. Therefore,
given the established link between tobacco smoking and lung
cancer, confounding by tobacco smoking is one of the major
concerns in studies attempting to elucidate the association
between cannabis smoking and lung cancer. In this study, we
found habitual cannabis users were much more likely than
nonhabitual or never users to be tobacco smokers (86.3% vs.
64.0%, p< 0.001). Similarly, tobacco smokers were more
likely than never smokers to use cannabis habitually (13.8%
vs. 4.3%, p< 0.001). Comparing cannabis users who also
smoked tobacco versus those who used cannabis alone, users
of both products were more likely to be males and with low
to medium education levels (data not shown). We expect
that the association of cannabis and tobacco smoking would
lead to upward confounding of the cannabis association with
lung cancer, and that misclassification of cigarette consump-
tion would be a source of overestimating the strength of the
cannabis-lung cancer association in our data.
One of the key advantages of this pooled analysis was the
examination of the association between cannabis smoking
and lung cancer among never tobacco smokers, and these
findings were consistent with the results in the total sample.
The use of random-effect models in the pooled analysis
reduced the likelihood of larger studies overly influencing the
effect estimates. Since all studies in this pooled analysis were
case-control studies, and medical cannabis may have been
used by some to alleviate pain caused by cancer or pre-
cancer symptoms, there is possible reverse causality. How-
ever, our results did not change after excluding any cannabis
exposures within 2 years prior to the date of diagnosis or
interview (data not shown), arguing against reverse causality.
Our pooled results are consistent with a previous system-
atic review of observational studies on the association
between marijuana smoking and lung cancer, which also
found no association after adjusting for tobacco use.31 How-
ever, in a pooled analysis of three studies conducted in
Maghreb restricted to men, the OR was 2.3 (95% CI: 1.5–3.6)
for ever cannabis smoking comparing lung cancer cases to
hospital-based controls, after adjusting for tobacco smoking
Figure 1. Forest plot of the association between cannabis smoking (habitual vs. nonhabitual) and lung cancer risk. Pooled, pooled OR
according to a random effects model (p-heterogeneity50.17). Abbreviations: No.: Number; Exp.: Number exposed; CI: confidence interval.
MSH-PMH study, The Mount Sinai Hospital-Princess Margaret Hospital Study; MSKCC study, The Memorial Sloan-Kettering Cancer Center
Study; UCLA study, The University of California at Los Angeles Study.
E
pi
de
m
io
lo
gy
900 Cannabis smoking and lung cancer
Int. J. Cancer: 136, 894–903 (2015) VC 2014 UICC
and other potential confounders.17 The investigators of that
study also observed an increased risk of lung cancer with
increasing joint-years.17 But as the authors pointed out, the
practice of mixing of tobacco with cannabis in the region would
lead to upward residual confounding by tobacco smoking. In a
recently published 40-year cohort study among Swedish military
conscripts, a positive association was observed between heavy
cannabis smoking (defined as more than 50 times in total) at
baseline and lung–cancer incidence32; however, there are impor-
tant concerns regarding potential reporting bias, association of
tobacco and cannabis smoking behaviors (especially changes in
such behaviors since cohort entry), and residual confounding
by tobacco smoking, all of which may have affected the validity
of the findings.
The dose of cannabis product consumption differs by
source of plant material, its processing, and by smoking tech-
niques including the depth of inhalation and breath-holding,
number and frequency of puffs, as well as how much of the
joint is smoked. In addition, the amount of combustion by-
product varies by the mode of consumption. Because of the
varied levels of information collected by individual studies,
we were unable to examine these effects in this pooled analy-
sis. We observed interstudy heterogeneity, and it is possible
that this heterogeneity is due to differing characteristics of
the individual studies such as the prevailing cannabis product
being consumed in the study region, and differential recall
bias between in-person versus self-administered questionnaire
formats. Because of the limited number of studies, we were
unable to fully explore such sources of heterogeneity using
meta-regression. However, we detected no difference in the
pooled ORs between population-based case-control studies
and hospital or clinic-based studies. The study that contrib-
uted most of the observed heterogeneity is the New Zealand
study, which is also the study that reported the strongest
association between cannabis smoking and lung cancer risk.
The exclusion of this study resulted in the ORs closer to null,
with a much reduced heterogeneity.
Cannabis use is under international control and its legal
status varies, so reporting bias is of concern. The reported
prevalence among controls in the study populations is
Table 4. Risk estimates for the association between Cannabis smoking characteristics and lung cancer risk, results for adenocarcinoma
Cannabis smoking characteristics
Adenocarcinoma cases only
Cases
(n5913)
Controls
(n52,985)
No. of
studies
Pooled OR1
(95% CI) Het (P) I2No. % No. %
Status1
Nonhabitual smoker2 812 (89) 2664 (89) 1.00 (Ref)
Habitual 101 (11) 321 (11) 6 0.99 (0.73–1.33) 0.58 0.00
Intensity (joints/day)1
Nonhabitual smoker2 812 (89) 2664 (90) 1.00 (Ref)
<1 41 (5) 178 (6) 5 0.72 (0.48–1.10) 0.71 0.00
1 58 (6) 133 (4) 5 1.73 (0.75–4.00) 0.05 57.87
Continuous 5 1.04 (0.93–1.17) 0.27 21.88
Duration, years1
Nonhabitual smoker2 812 (89) 2664 (89) 1.00 (Ref)
>0 to <20 62 (7) 226 (8) 6 0.98 (0.69–1.39) 0.92 0.00
20 39 (4) 95 (3) 5 1.08 (0.60–1.96) 0.27 22.92
Continuous 6 0.99 (0.97–1.02) 0.12 43.05
Joint-years1
Nonhabitual smoker (<1)1 812 (89) 2664 (90) 1.00 (Ref)
1 to <10 37 (4) 180 (6) 5 0.67 (0.41–1.11) 0.36 7.44
10 62 (7) 132 (4) 5 1.74 (0.85–3.56) 0.09 50.34
Continuous 5 1.00 (0.99–1.00)3 0.97 0.00
1Random effect model (Study-specific models adjusted for age, sex, race, highest education, tobacco smoking status and tobacco smoking pack-
years. Exceptions are models for continuous variables for Moffitt Cancer Study and Memorial Sloan-Kettering Cancer Center Study, which were
adjusted for age, sex and tobacco smoking pack-years as the base.
2Nonhabitual cannabis smoker is defined as ones with cumulative cannabis consumption of less than 1 joint-year (equivalent of 1 joint per day for
1 year), including never users.
3Summary OR based on 5 studies excluding New Zealand (OR51.11, 95%CI 1.04–1.19), p-value for heterogeneity when it is included5 0.04.
Abbreviations: CI, confidence interval; Het, heterogeneity; No., number.
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comparable to nation or region-specific survey results.33–35
Greater under-reporting by cases as compared to controls
might explain the lack of observed association.
Cannabis is usually smoked without a filter, and smoking
dynamics studies among habitual marijuana users show that
the overall burden of particulates delivered to the respiratory
tract is about 4 times greater when smoking marijuana than
when smoking the same amount of tobacco.8 When com-
pared to tobacco smoke, cannabis tends to burn at a higher
temperature (which may accelerate biochemical processes)
and cannabis smoke is typically inhaled deeper and held lon-
ger.36 On the other hand, the quantity of cannabis smoked
by chronic users is typically far less than the quantity of
tobacco smoked by chronic cigarette smokers.
Other potential health effects of cannabis smoking that have
been reported include those on the cardiovascular system,37–39 the
development of drug dependence, and subtle cognitive impair-
ment. Inconclusive findings of cannabis use being associated with
mild changes in pulmonary function40–44 have also been reported,
as have its benefits on fasting glucose.45 The changing social and
legal status of cannabis in the United States may however compli-
cate the picture by altering patterns of consumption methods.
Specifically, respiratory risks may differ with the use of water pipes
and vaporizers or with consuming oral preparations.
Figure 2. Restricted cubic spline (5 knots) to explore nonlinear association between cannabis smoking and lung cancer risk in all subjects
showing the fitted odds of being a case versus being a control under different exposure measurements: (a) Joint-equivalents per day; (b)
Duration; (c) Joint-years. Gray area, 95% confidence interval. Each model was adjusted for age, sex, race, highest education, tobacco smok-
ing status and packyears, and study.
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Given the popularity of cannabis use, particularly among
younger populations, it is important to have reliable estimates
of health consequences. Our study highlights the need for
comprehensive and standardized measures of quantity and
methods of cannabis consumption, along with accurate meas-
ures of tobacco consumption to insure confounding control.
To address the small sample size with very high exposures
and histological subtypes (other than adenocarcinoma),
future epidemiologic studies need to include sufficient num-
bers of heavy users and specific histological subtypes of inter-
ests. Prospective follow-up studies of the health effects are
also needed.
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